Interstitial lung diseases and autoimmunity

Lung disease is one of the most common manifestations of systemic autoimmune rheumatic diseases (SARDs), involving all parts of the respiratory system in the pathological process. Interstitial lung diseases (ILD) are of great importance and often lead to the development of progressive pulmonary fibrosis (PPF). The following clinical categories of patients are distinguished within ILDs associated with SARDs (ILD-SARDs): ILD in patients with a reliable diagnosis of SARDs; ILD as the first manifestation of SARDs; ILD or interstitial pneumonia with autoimmune features. Clinical phenotypes of ILD-SARDs vary from «asymptomatic» to «rapidly progressing» are related with risk factors for progressive lung damage. These phenotypes should be considered for conducting clinical, laboratory and instrumental screening and prescribing anti-inflammatory or antifibrotic therapy. In the pulmonology practice a patient with ILD may have previously established SARDs, or this diagnosis could be suspected based on a number of clinical symptoms of rheumatic diseases. Problem of ILD-SARDs diagnostic is very complex, which determines a multidisciplinary approach based on the interaction with rheumatologists, pulmonologists and radiologists. The possibilities and perspectives for pharmacotherapy of ILD-SARDs are based on the rational use of anti-inflammatory, immunomodulatory and antifibrotic drugs. The following issues related to pharmacotherapy of ILD-SARDs should be emphasized: identification of patients with a rapidly progressing phenotype of pulmonary fibrosis; the contribution of inflammatory activity; the effectiveness of therapy in relation to the leading “extrapulmonary” manifestations of SARDs and pneumotoxicity within the implementation of the “treat to target” concept. The greatest achievement in the pharmacotherapy of autoimmune diseases is associated with the use of chimeric antigen receptor (CAR) T-cell therapy, which mechanism is associated with the elimination of pathogenic autoreactive B-cells. Preliminary data of CAR T-cell therapy indicate the high efficacy in a wide range of clinical manifestations of SARDs, including the progression of ILD in patients with systemic sclerosis and antisynthetase syndrome, and there are strong evidence of the important role of autoimmune mechanisms in the pathogenesis of ILD.

1. Rosenblum MD, Remedios KA, Abbas AK. Mechanisms of human autoimmunity. J Clin Invest. 2015;125(6):2228-233. doi: 10.1172/JCI78088

2. Nasonov EL. Modern concept of autoimmunity in rheumatology. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2023;61(4):397-420 (In Russ.). doi: 10.47360/1995-4484-2023-397-420

3. Pisetsky DS. Pathogenesis of autoimmune disease. Nat Rev Nephrol. 2023;19(8):509-524. doi: 10.1038/s41581-023-00720-1

4. Nasonov EL, Aleksandrova EN, Novikov AA. Autoimmune rheumatic diseases – problems of immunopathology and personalized treatment. Annals of the Russian Academy of Medical Sciences. 2015;70(2):169-182. (In Russ.). doi: 10.15690/vramn.v70i2.1310

5. Wang L, Wang FS, Gershwin ME. Human autoimmune diseases: A comprehensive update. J Intern Med. 2015;278(4):369-395. doi: 10.1111/joim.12395

6. Doyle TJ, Dellaripa PF. Lung manifestations in the rheumatic diseases. Chest. 2017;152(6):1283-1295. doi: 10.1016/j.chest.2017.05.015

7. Fischer A, du Bois R. Interstitial lung disease in connective tissue disorders. Lancet. 2012;380(9842):689-698. doi: 10.1016/S0140-6736(12)61079-4

8. Good SD, Sparks JA, Volkmann ER. Screening, diagnosis, and monitoring of interstitial lung disease in autoimmune rheumatic diseases: A narrative review. Rev Colomb Reumatol. 2024;31(Suppl 1):S3-S14. doi: 10.1016/j.rcreu.2023.06.002

9. Matson SM, Demoruelle MK. Connective tissue disease associated interstitial lung disease. Rheum Dis Clin North Am. 2024;50(3):423-438. doi: 10.1016/j.rdc.2024.03.001

10. Nasonov EL, Ananyeva LP, Avdeev SN. Interstitial lung disease in rheumatoid arthritis: A multidisciplinary problem in rheumatology and pulmonology. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2022;60(6):517-534 (In Russ.). doi: 10.47360/1995-4484-2022-1

11. Hyldgaard C, Bendstrup E, Pedersen AB, Pedersen L, Ellingsen T. Interstitial lung disease in connective tissue diseases: Survival patterns in a population-based cohort. J Clin Med. 2021;10(21):4830. doi: 10.3390/jcm10214830

12. Mukherjee M, Kolb M. A novel take on idiopathic pulmonary fibrosis disease progression: Localised autoimmunity. Eur Respir J. 2023;61(5):2300653. doi: 10.1183/13993003.00653-2023

13. Dong LL, Liu ZY, Chen KJ, Li ZY, Zhou JS, Shen HH, et al. The persistent inflammation in COPD: Is autoimmunity the core mechanism? Eur Respir Rev. 2024;33(171):230137. doi: 10.1183/16000617.0137-2023

14. Starshinova AA, Malkova AM, Basantsova NY, Zinchenko YS, Kudryavtsev IV, Ershov GA, et al. Sarcoidosis as an autoimmune disease. Front Immunol. 2020;10:2933. doi: 10.3389/fimmu.2019.02933

15. Nasonov EL. Coronavirus disease 2019 (COVID-19) pandemic and autoimmune rheumatic diseases: Outcomes and prospects. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2024;62(1):32-54 (In Russ.). doi: 10.47360/1995-4484-2024-32-54

16. David P, Sinha S, Iqbal K, De Marco G, Taheri S, McLaren E, et al. MDA5-autoimmunity and interstitial pneumonitis contemporaneous with the COVID-19 pandemic (MIP-C). EBioMedicine. 2024;104:105136. doi: 10.1016/j.ebiom.2024.105136

17. Johnson SR, Bernstein EJ, Bolster MB, Chung JH, Danoff SK, George MD, et al. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) guideline for the screening and monitoring of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Rheumatol. 2024;76(8):1201-1213. doi: 10.1002/art.42860

18. Guiot J, Miedema J, Cordeiro A, De Vries-Bouwstra JK, Dimitroulas T, Søndergaard K, et al. Practical guidance for the early recognition and follow-up of patients with connective tissue disease-related interstitial lung disease. Autoimmun Rev. 2024;23(6):103582. doi: 10.1016/j.autrev.2024.103582

19. Johnson SR, Bernstein EJ, Bolster MB, Chung JH, Danoff SK, George MD, et al. 2023 American College of Rheumatology (ACR)/American College of Chest Physicians (CHEST) guideline for the treatment of interstitial lung disease in people with systemic autoimmune rheumatic diseases. Arthritis Rheumatol. 2024;76(8):1182-1200. doi: 10.1002/art.42861

20. Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, et al.; ATS/ERS Committee on Idiopathic Interstitial Pneumonias. An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med. 2013;188(6):733-748. doi: 10.1164/rccm.201308-1483ST

21. Joy GM, Arbiv OA, Wong CK, Lok SD, Adderley NA, Dobosz KM, et al. Prevalence, imaging patterns and risk factors of interstitial lung disease in connective tissue disease: A systematic review and meta-analysis. Eur Respir Rev. 2023;32(167):220210. doi: 10.1183/16000617.0210-2022

22. Panagopoulos P, Goules A, Hoffmann-Vold AM, Matteson EL, Tzioufas A. Natural history and screening of interstitial lung disease in systemic autoimmune rheumatic disorders. Ther Adv Musculoskelet Dis. 2021;13:1759720X211037519. doi: 10.1177/1759720X211037519

23. Zhu W, Zhou C, Sun X, Xue P, Li Z, Zhang W, et al. Interstitial lung diseases associated with ANCA positivity: A different disease spectrum from interstitial pneumonia with autoimmune features. Respir Med Res. 2024;86:101111. doi: 10.1016/j.resmer.2024.101111

24. Fischer A, Antoniou KM, Brown KK, Cadranel J, Corte TJ, du Bois RM, et al.; “ERS/ATS Task Force on Undifferentiated Forms of CTD-ILD”. An official European Respiratory Society/ American Thoracic Society research statement: Interstitial pneumonia with autoimmune features. Eur Respir J. 2015;46(4):976- 987. doi: 10.1183/13993003.00150-2015

25. Akulkina LA, Brovko MYu, Sholomova VI, Yanakaeva AS, Moiseev SV. Interstitial pneumonia with autoimmune features (IPAF): Multidisciplinary diagnosis in pulmonology and rheumatology. Clinical Pharmacology and Therapy. 2018;27(5): 5-10. (In Russ.). doi: 10.32756/0869-5490-2018-5-5-10

26. Akulkina LA, Shchepalina AA, Moiseev AS, Brovko MY, Sholomova VI, Moiseev SV. Interstitial pneumonia with autoimmune features: Monocentric prospective study. Terapevticheskii arkhiv. 2023;95(3):224-229 (In Russ.). doi: 10.26442/00403660.2023.03.202087

27. Mosca M, Tani C, Vagnani S, Carli L, Bombardieri S. The diagnosis and classification of undifferentiated connective tissue diseases. J Autoimmun. 2014;48-49:50-52. doi: 10.1016/j.jaut.2014.01.019

28. Ma WT, Chang C, Gershwin ME, Lian ZX. Development of autoantibodies precedes clinical manifestations of autoimmune diseases: A comprehensive review. J Autoimmun. 2017;83:95-112. doi: 10.1016/j.jaut.2017.07.003

29. Bieber K, Hundt JE, Yu X, Ehlers M, Petersen F, Karsten CM, et al. Autoimmune pre-disease. Autoimmun Rev. 2023;22(2):103236. doi: 10.1016/j.autrev.2022.103236

30. Sambataro G, Sambataro D, Spicuzza L, Meloni F, Lorini G, Malatino L, et al. Progression and prognosis of interstitial pneumonia with autoimmune features: A longitudinal, prospective, multi-centre study. Clin Exp Rheumatol. 2023;41(5):1140-1148. doi: 10.55563/clinexprheumatol/lycdca

31. Sambataro G, Vancheri A, Torrisi SE, Colaci M, Pavone M, Libra A, et al. The morphological domain does not affect the rate of progression to defined autoimmune diseases in patients with interstitial pneumonia with autoimmune features. Chest. 2020;157(1):238-242. doi: 10.1016/j.chest.2019.08.2175

32. Biciusca V, Rosu A, Stan SI, Cioboata R, Biciusca T, Balteanu MA, et al. A practical multidisciplinary approach to identifying interstitial lung disease in systemic autoimmune rheumatic diseases: A clinician’s narrative review. Diagnostics (Basel). 2024;14(23):2674. doi: 10.3390/diagnostics14232674

33. Walsh SLF, Wells AU, Desai SR, Poletti V, Piciucchi S, Dubini A, et al. Multicentre evaluation of multidisciplinary team meeting agreement on diagnosis in diffuse parenchymal lung disease: A case-cohort study. Lancet Respir Med. 2016;4:557-565. doi: 10.1016/S2213-2600(16)30033-9

34. Glenn LM, Troy LK, Corte TJ. Diagnosing interstitial lung disease by multidisciplinary discussion: A review. Front Med (Lausanne). 2022;9:1017501. doi: 10.3389/fmed.2022.1017501

35. Levi Y, Israeli-Shani L, Kuchuk M, Epstein Shochet G, Koslow M, Shitrit D. Rheumatological assessment is important for interstitial lung disease diagnosis. J Rheumatol. 2018;45:1509- 1514. doi: 10.3899/jrheum.171314

36. Guler SA, Scheschkowski T, Renner A, Kämpf L, Gasser M, Britta Maurer B. Interdisciplinary diagnosis and management of patients with interstitial lung disease and connective tissue disease. Chest. 2024;166(2):352-361. doi: 10.1016/j.chest.2024.02.045

37. Burbelo PD, Iadarola MJ, Keller JM, Warner BM. Autoantibodies targeting intracellular and extracellular proteins in autoimmunity. Front Immunol. 2021;12:548469. doi: 10.3389/fimmu.2021.548469

38. Ludwig RJ, Vanhoorelbeke K, Leypoldt F, Kaya Z, Bieber K, McLachlan SM, et al. Mechanisms of autoantibody-induced pathology. Front Immunol. 2017;8:603. doi: 10.3389/fimmu.2017.00603

39. Lastwika KJ, Lampe PD. Breaking tolerance: Autoantibodies can target protein posttranslational modifications. Curr Opin Biotechnol. 2024;85:103056. doi: 10.1016/j.copbio.2023.103056

40. Kuwana M, Gil-Vila A, Selva-O’Callaghan A. Role of autoantibodies in the diagnosis and prognosis of interstitial lung disease in autoimmune rheumatic disorders. Ther Adv Musculoskelet Dis. 2021;13:1759720X211032457. doi: 10.1177/1759720X211032457

41. Allameen NA, Ramos-Lisbona AI, Wedderburn LR, Lundberg IE, Isenberg DA. An update on autoantibodies in the idiopathic inflammatory myopathies. Nat Rev Rheumatol. 2025;21(1):46-62. doi: 10.1038/s41584-024-01188-4

42. Xie S, Li S, Chen B, Zhu Q, Xu L, Li F. Serum anti-citrullinated protein antibodies and rheumatoid factor increase the risk of rheumatoid arthritis-related interstitial lung disease: A meta-analysis. Clin Rheumatol. 2021;40(11):4533-4543. doi: 10.1007/s10067-021-05808-2

43. Li Y, Gao X, Li Y, Jia X, Zhang X, Xu Y, et al. Predictors and mortality of rapidly progressive interstitial lung disease in patients with idiopathic inflammatory myopathy: A series of 474 patients. Front Med (Lausanne). 2020;7:363. doi: 10.3389/fmed.2020.00363

44. Damoiseaux J, von Mühlen CA, Garcia-De La Torre I, Carballo OG, de Melo Cruvinel W, Francescantonio PL, et al. International consensus on ANA patterns (ICAP): The bumpy road towards a consensus on reporting ANA results. Auto Immun Highlights. 2016;7(1):1. doi: 10.1007/s13317-016-0075-0

45. Yao J, Wang J, Guo L, Su P, Li J, Li B. Determinants for worsening in systemic autoimmune rheumatic disease-associated interstitial lung disease: A systematic review and meta-analysis of cohort studies. Front Med (Lausanne). 2024;11:1465753. doi: 10.3389/fmed.2024.1465753

46. Vuillard C, Pineton de Chambrun M, de Prost N, Guérin C, Schmidt M, Dargent A, et al. Clinical features and outcome of patients with acute respiratory failure revealing anti-synthetase or anti-MDA-5 dermato-pulmonary syndrome: A French multicenter retrospective study. Ann Intensive Care. 2018;8(1):87. doi: 10.1186/s13613-018-0433-3

47. Zhang T, Shen P, Duan C, Gao L. KL-6 as an immunological biomarker predicts the severity, progression, acute exacerbation, and poor outcomes of interstitial lung disease: A systematic review and meta-analysis. Front Immunol. 2021;12:745233. doi: 10.3389/fimmu.2021.745233

48. d’Alessandro M, Cameli P, Cotton CV, Lamb JA, Bergantini L, Gangi S, et al. Panel of serum biomarkers for differential diagnosis of idiopathic interstitial lung disease and interstitial lung diseasesecondary to systemic autoimmune rheumatic disease. PLoS One. 2024;19(10):e0311357. doi: 10.1371/journal.pone.0311357

49. Hannah J, Rodziewicz M, Mehta P, Heenan KM, Ball E, Barratt S, et al. The diagnosis and management of systemic autoimmune rheumatic disease-related interstitial lung disease: British Society for Rheumatology guideline scope. Rheumatol Adv Pract. 2024;8(2):rkae056. doi: 10.1093/rap/rkae056

50. Weng C, Zhou Y, Zhang L, Wang G, Ding Z, Xue L, et al. Efficacy and safety of pharmacological treatments for autoimmune disease-associated interstitial lung disease: A systematic review and network meta-analysis. Semin Arthritis Rheum. 2024;68:152500. doi: 10.1016/j.semarthrit.2024.152500

51. Higuero Sevilla JP, Memon A, Hinchcliff M. Learnings from clinical trials in patients with connective tissue disease-associated interstitial lung disease. Arthritis Res Ther. 2023;25(1):118. doi: 10.1186/s13075-023-03090-y

52. Finnerty JP, Ponnuswamy A, Dutta P, Abdelaziz A, Kamil H. Efficacy of antifibrotic drugs, nintedanib and pirfenidone, in treatment of progressive pulmonary fibrosis in both idiopathic pulmonary fibrosis (IPF) and non-IPF: A systematic review and meta-analysis. BMC Pulm Med. 2021;21(1):411. doi: 10.1186/s12890-021-01783-1

53. Koduri G, Solomon JJ. Identification, monitoring, and management of rheumatoid arthritis-associated interstitial lung disease. Arthritis Rheumatol. 2023;75(12):2067-2077. doi: 10.1002/art.42640

54. Akiyama M, Alshehri W, Kaneko Y. Does a window of opportunity for rheumatoid arthritis-associated interstitial lung disease exist? Autoimmun Rev. 2024;23(2):103501. doi: 10.1016/j.autrev.2023.103501

55. Yuan H, Cui S, Yang L, Cui J, Wang X, Ding M, et al. Efficacy of non-conventional synthetic DMARDs for patients with rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis. RMD Open. 2023;9(4):e003487. doi: 10.1136/rmdopen-2023-003487

56. Sullivan DI, Ascherman DP. Rheumatoid arthritis-associated interstitial lung disease (RA-ILD): Update on prevalence, risk factors, pathogenesis, and therapy. Curr Rheumatol Rep. 2024;26(12):431-449. doi: 10.1007/s11926-024-01155-8

57. Teel A, Lu J, Park J, Singh N, Basharat P. The role of myositisspecific autoantibodies and the management of interstitial lung disease in idiopathic inflammatory myopathies: A systematic review. Semin Arthritis Rheum. 2022;57:152088. doi: 10.1016/j.semarthrit.2022.152088

58. Bautista-Sanchez R, Khanna D. Systemic sclerosis-associated interstitial lung disease: How to manage in 2024? Rheumatol Immunol Res. 2024;5(3):157-165. doi: 10.2478/rir-2024-0022

59. Rahaghi FF, Hsu VM, Kaner RJ, Mayes MD, Rosas IO, Saggar R, et al. Expert consensus on the management of systemic sclerosis-associated interstitial lung disease. Respir Res. 2023;24(1):6. doi: 10.1186/s12931-022-02292-3

60. Lescoat A, Bertoldo E, Čolić J, Santiago T, Suliman YA, Emmel J, et al. Results from the international collaborative systematic literature review informing the 2023 EULAR recommendations for the treatment of systemic sclerosis. Ann Rheum Dis. 2025;84(1):77-92. doi: 10.1136/ard-2024-226429

61. Raghu G, Montesi SB, Silver RM, Hossain T, Macrea M, Herman D, et al. Treatment of systemic sclerosis-associated interstitial lung disease: Evidence-based recommendations. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2024;209(2):137-152. doi: 10.1164/rccm.202306-1113ST

62. Pope JE, Denton CP, Johnson SR, Fernandez-Codina A, Hudson M, Nevskaya T. State-of-the-art evidence in the treatment of systemic sclerosis. Nat Rev Rheumatol. 2023;19(4):212-226. doi: 10.1038/s41584-023-00909-5

63. Yamakawa H, Toyoda Y, Baba T, Kishaba T, Fukuda T, Takemura T, et al. Anti-inflammatory and/or anti-fibrotic treatment of MPO-ANCA-positive interstitial lung disease: A short review. J Clin Med. 2022;11(13):3835. doi: 10.3390/jcm11133835

64. Ahmed S, Handa R. Management of connective tissue diseaserelated interstitial lung disease. Curr Pulmonol Rep. 2022;11(3):86- 98. doi: 10.1007/s13665-022-00290-w

65. Ghazipura M, Mammen MJ, Herman DD, Hon SM, Bissell BD, Macrea M, et al. Nintedanib in progressive pulmonary fibrosis: A systematic review and meta-analysis. Ann Am Thorac Soc. 2022;19(6):1040-1049. doi: 10.1513/AnnalsATS.202103-343OC

66. Ananieva LP, Avdeev SN, Tyurin IЕ, Lila AМ, Zagrebneva AI, Maslyanskiy АL, et al. Chronic fibrosing interstitial lung disease with progressive phenotype. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2020;58(6):631-636 (In Russ.). doi: 10.47360/1995-4484-2020-631-636

67. Raghu G, Remy-Jardin M, Richeldi L, Thomson CC, Inoue Y, Johkoh T, et al. Idiopathic pulmonary fibrosis (an update) and progressive pulmonary fibrosis in adults: An official ATS/ ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med. 2022;205(9):e18-e47. doi: 10.1164/rccm.202202-0399ST

68. Tzilas V, Tzouvelekis A, Ryu JH, Bouros D. 2022 update on clinical practice guidelines for idiopathic pulmonary fibrosis and progressive pulmonary fibrosis. Lancet Respir Med. 2022;10(8):729- 731. doi: 10.1016/S2213-2600(22)00223-5

69. Lombardi F, Stewart I, Fabbri L, Adams W, Kawano-Dourado L, Ryerson CJ, et al.; REMAP-ILD Consortium. Mycophenolate and azathioprine efficacy in interstitial lung disease: A systematic review and meta-analysis. BMJ Open Respir Res. 2024;11(1):e002163. doi: 10.1136/bmjresp-2023-002163

70. Mankikian J, Caille A, Reynaud-Gaubert M, Agier MS, Bermudez J, Bonniaud P, et al.; EVER-ILD investigators and the OrphaLung network. Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): A doubleblind, randomised, placebo-controlled trial. Eur Respir J. 2023;61(6):2202071. doi: 10.1183/13993003.02071-2022

71. Mansy L, Caille A, Reynaud-Gaubert M, Bermudez J, Bonniaud P, Borie R, et al.; EVER-ILD investigators and the OrphaLung network. Rituximab and mycophenolate mofetil in interstitial lung disease (EVER-ILD): 1-year follow-up results of a randomised controlled trial. Eur Respir J. 2024;64(3):2401368. doi: 10.1183/13993003.01368-2024

72. Fernández-Díaz C, Castañeda S, Melero-González RB, OrtizSanjuán F, Juan-Mas A, Carrasco-Cubero C, et al. Abatacept in interstitial lung disease associated with rheumatoid arthritis: National multicenter study of 263 patients. Rheumatology (Oxford). 2020;59(12):3906-3916. doi: 10.1093/rheumatology/keaa621

73. Fernández-Díaz C, Atienza-Mateo B, Castañeda S, Melero-Gonzalez RB, Ortiz-SanJuan F, Loricera J, et al.; Spanish Collaborative Group of Interstitial Lung Disease Associated with Rheumatoid Arthritis. Abatacept in monotherapy vs combined in interstitial lung disease of rheumatoid arthritis – Multicentre study of 263 Caucasian patients. Rheumatology (Oxford). 2021;61(1):299- 308. doi: 10.1093/rheumatology/keab317

74. Atienza-Mateo B, Fernández-Díaz C, Vicente-Rabaneda EF, Melero-González RB, Ortiz-Sanjuán F, Casafont-Solé I, et al.; Spanish Collaborative Group of Abatacept in Interstitial Lung Disease Associated with Rheumatoid Arthritis. Abatacept in usual and in non-specific interstitial pneumonia associated with rheumatoid arthritis. Eur J Intern Med. 2024;119:118-124. doi: 10.1016/j.ejim.2023.08.025

75. López-Maraver M, Serrano-Combarro A, Atienza-Mateo B, Del Val N, Casafont-Solé I, Melero-Gonzalez RB, et al.; Spanish Collaborative Group of Abatacept in Interstitial Lung Disease Associated with Rheumatoid Arthritis. Subcutaneous vs intravenous abatacept in rheumatoid arthritis-interstitial lung disease. National multicentre study of 397 patients. Semin Arthritis Rheum. 2024;68:152517. doi: 10.1016/j.semarthrit.2024.152517

76. Tardella M, Di Carlo M, Carotti M, Giovagnoni A, Salaffi F. Abatacept in rheumatoid arthritis-associated interstitial lung disease: Short-term outcomes and predictors of progression. Clin Rheumatol. 2021;40(12):4861-4867. doi: 10.1007/s10067-021-05854-w

77. Tsujii A, Isoda K, Yoshimura M, Nakabayashi A, Kim DS, Tamada T, et al. Janus kinase inhibitors vs. abatacept about safety and efficacy for patients with rheumatoid arthritis-associated interstitial lung disease: A retrospective nested case-control study. BMC Rheumatol. 2024;8(1):4. doi: 10.1186/s41927-024-00374-x

78. Mochizuki T, Yano K, Ikari K, Okazaki K. Radiological evaluation of interstitial lung disease in patients with rheumatoid arthritis treated with abatacept or JAK inhibitors for 1 year. Respir Investig. 2023;61(3):359-363. doi: 10.1016/j.resinv.2023.02.007

79. Shoda T, Kotani T, Koyama M, Yoshikawa A, Wada Y, Makino H, et al. The therapeutic efficacy of abatacept for rheumatoid arthritis-associated interstitial lung disease: Insights from a 12-month trial using semi-quantitative chest high-resolution computed tomography imaging. J Clin Med. 2024;13(19):5871. doi: 10.3390/jcm13195871

80. Mena-Vázquez N, Rojas-Gimenez M, Fuego-Varela C, GarcíaStuder A, Perez-Gómez N, Romero-Barco CM, et al. Safety and effectiveness of abatacept in a prospective cohort of patients with rheumatoid arthritis-associated interstitial lung disease. Biomedicines. 2022;10(7):1480. doi: 10.3390/biomedicines10071480

81. Narváez J, Aguilar-Coll M, Roig-Kim M, Maymó-Paituvi P, Palacios-Olid J, Nolla JM, et al. Janus kinase inhibitors in rheumatoid arthritis-associated interstitial lung disease: A systematic review and meta-analysis. Autoimmun Rev. 2024;23(10):103636. doi: 10.1016/j.autrev.2024.103636

82. Paik JJ, Lubin G, Gromatzky A, Mudd PN Jr, Ponda MP, Christopher-Stine L. Use of Janus kinase inhibitors in dermatomyositis: A systematic literature review. Clin Exp Rheumatol. 2023;41(2):348- 358. doi: 10.55563/clinexprheumatol/hxin6o

83. Shan X, Wu S, Chen X, Ge Y. Janus kinase inhibition (JAKi) therapy in refractory anti-synthetase syndrome: A retrospective cohort study. Semin Arthritis Rheum. 2024;68:152474. doi: 10.1016/j.semarthrit.2024.152474

84. Yasui M, Iwamoto T, Furuta S. New therapies in anti-MDA5 antibody-positive dermatomyositis. Curr Opin Rheumatol. 2024;36(1):61-68. doi: 10.1097/BOR.0000000000000979

85. Fiorentini E, Bonomi F, Peretti S, Orlandi M, Lepri G, Matucci Cerinic M, et al. Potential role of JAK inhibitors in the treatment of systemic sclerosis-associated interstitial lung disease: A narrative review from pathogenesis to real-life data. Life (Basel). 2022;12(12):2101. doi: 10.3390/life12122101

86. Herman D, Ghazipura M, Barnes H, Macrea M, Knight SL, Silver RM, et al. Nintedanib therapy alone and combined with mycophenolate in patients with systemic sclerosis-associated interstitial lung disease: Systematic reviews and meta-analysis. Ann Am Thorac Soc. 2024;21(3):474-485. doi: 10.1513/AnnalsATS.202301-081OC

87. Nieto MA, Sanchez-Pernaute O, Vadillo C, Rodriguez-Nieto MJ, Romero-Bueno F, López-Muñiz B, et al.; NEREA Group. Functional respiratory impairment and related factors in patients with interstitial pneumonia with autoimmune features (IPAF): Multicenter study from NEREA registry. Respir Res. 2023 18;24(1):19. doi: 10.1186/s12931-023-02317-5

88. Chen T, Li QH, Zhang Y, Yin CS, Weng D, Zhou Y, et al. The role of pirfenidone in the treatment of interstitial pneumonia with autoimmune features. Clin Exp Rheumatol. 2022;40(3):560- 567. doi: 10.55563/clinexprheumatol/off5n7

89. Schett G, Mackensen A, Mougiakakos D. CAR T-cell therapy in autoimmune diseases. Lancet. 2023;402(10416):2034-2044. doi: 10.1016/S0140-6736(23)01126-1

90. Nasonov EL, Rumyantsev AG, Samsonov MYu. Pharmacotherapy of autoimmune rheumatic diseases – from monoclonal antibodies to CAR T cells: 20 years later. Nauchno-Prakticheskaya Revmatologia = Rheumatology Science and Practice. 2024;62(3):262-279 (In Russ.). doi: 10.47360/1995-4484-2024-262-279

91. Müller F, Taubmann J, Bucci L, Wilhelm A, Bergmann C, Völkl S, et al. CD19 CAR T-cell therapy in autoimmune disease – A case series with follow-up. N Engl J Med. 2024;390(8):687-700. doi: 10.1056/NEJMoa2308917

92. Bergmann C, Müller F, Distler JHW, Györfi AH, Völkl S, Aigner M, et al. Treatment of a patient with severe systemic sclerosis (SSc) using CD19-targeted CAR T cells. Ann Rheum Dis. 2023;82(8):1117-1120. doi: 10.1136/ard-2023-223952

93. Merkt W, Freitag M, Claus M, Kolb P, Falcone V, Röhrich M, et al. Third-generation CD19 CAR-T cell-containing combination therapy in Scl70+ systemic sclerosis. Ann Rheum Dis. 2024;83(4):543-546. doi: 10.1136/ard-2023-225174

94. Müller F, Boeltz S, Knitza J, Aigner M, Völkl S, Kharboutli S, et al. CD19-targeted CAR T cells in refractory antisynthetase syndrome. Lancet. 2023;401(10379):815-818. doi: 10.1016/S0140-6736(23)00023-5

95. Pecher AC, Hensen L, Klein R, Schairer R, Lutz K, Atar D, et al. CD19-Targeting CAR T cells for myositis and interstitial lung disease associated with antisynthetase syndrome. JAMA. 2023;329(24):2154-2162. doi: 10.1001/jama.2023.8753

96. Taubmann J, Knitza J, Müller F, Völkl S, Aigner M, Kleyer A, et al. Rescue therapy of antisynthetase syndrome with CD19-targeted CAR-T cells after failure of several B-cell depleting antibodies. Rheumatology (Oxford). 2024;63(1):e12-e14. doi: 10.1093/rheumatology/kead330